相关实验视频

Updated: Jun 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在低PD-L1表达性非状NSCLC的第一线免疫治疗中,基因突变导向化疗无策略

Hui Li¹, Jingjing Liu², Liang Zhang³

¹Translational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, Jilin, China.

Journal for immunotherapy of cancer

|November 30, 2024

概括

一个新的得分 (ISAC) 预测化学疗法对非小细胞肺癌的免疫疗法没有好处. 这一发现有助于个性化非状NSCLC的治疗,减少毒性和改善结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因组学就是基因组学.

背景情况:

在低PD-L1表达率 (<50%) 的非状非小细胞肺癌 (nsqNSCLC) 的第一线免疫治疗中,双化疗的必要性尚未得到研究.
生物标志物是必要的,以指导无化疗治疗决策,并最大限度地减少这种患者群的毒性.

研究的目的:

开发和验证一个预测生物标志物,以确定白金双重化疗在低PD-L1表达的nsqNSCLC的第一线免疫疗法中的必要性.
研究与化疗反应相关的免疫微环境.

主要方法:

对790名患有低PD-L1表达nsqNSCLC的患者进行分析,这些患者接受了免疫检查点抑制剂单疗法 (ICI-单疗法),化疗或组合治疗 (ICI-化疗).
开发和验证额外化疗 (ISAC) 的相互作用评分.
转录和多重免疫光数据分析,以评估免疫微环境.

主要成果:

与ICI单独治疗相比,ICI化疗显示了改善无进展生存率 (PFS) 和整体生存率 (OS) 的趋势.
化疗的益处在ISAC低分组 (PFS:HR=0.48,OS:HR=0.53) 中显著,但在ISAC高分组 (PFS:HR=1.08,OS:HR=1.14) 中没有显著.
高ISAC与适应性免疫抵抗有关,其特征是特定的免疫细胞概况和检查点表达 (不包括PD-L1).

结论:

一个高的ISAC得分预测了白金双重化疗对低PD-L1表达nsqNSCLC的第一线ICI治疗的最小附加益.
这种预测工具可以帮助个性化治疗策略,提高疗效和降低NSqNSCLC患者的毒性.

关键词:

生物标志物生物标志物免疫检查点抑制剂免疫检查点抑制剂肺癌肺癌是一种肺癌.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.